Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;35(4):468-477.
doi: 10.1007/s12250-020-00202-9. Epub 2020 Mar 10.

A Mother-to-Child Transmission Study in Nigeria: The Impact of Maternal HIV Infection and HAART on Plasma Immunoglobulins, Cytokine Profiles and Infant Outcome

Chinwe O Ewenighi-Amankwah  1   2 , Charles Chinedum Onyenekwe  3 , Ogochukwu Udemba  4 , Patience Muogbo  5 , Lijun Rong  6
Affiliations

A Mother-to-Child Transmission Study in Nigeria: The Impact of Maternal HIV Infection and HAART on Plasma Immunoglobulins, Cytokine Profiles and Infant Outcome

Chinwe O Ewenighi-Amankwah et al. Virol Sin. 2020 Aug.

Abstract

Prevention of mother-to-child transmission (PMTCT) of HIV with highly active antiretroviral therapy (HARRT) allows the HIV+ pregnant mothers to have vaginal delivery and breastfeed. Here we investigated the maternal plasma immunoglobulin, cytokine secretion and the outcome of the exposed infants among the HIV+ HAART treated pregnant women in Nigeria. In this study, different plasma immunoglobulins and cytokines were measured in the HIV+ HAART treated pregnant mothers. Pooled culture supernatants of B and T lymphocytes showed lower levels of IFN-γ, IL-10 and IL-4. There were lower IFN-γ and IL-10 secretions at 1st trimester; however, IL-10 continued to be lower throughout 2nd and 3rd trimesters. TNF-α secretion significantly decreased as pregnancy progressed to term. There were high plasma IgG and low IgM in the HIV+ HAART treated pregnant women. Plasma IgG was high during 1st and 3rd trimesters. After one year of follow up, all the exposed children were seronegative for HIV-1 and HIV-2. Vaginal delivery and breastfeeding among HIV+ HAART treated mothers have shown to be safe. The use of HAART by the infected mothers and the use of septrin and niverapin by the exposed infants prevented mother to-child transmission of HIV.

Keywords: Cytokine; Highly active antiretroviral therapy (HAART); Human immunodeficiency virus (HIV); Immunoglobulins; Lymphocyte stimulation; Mitogen; Prevention from mother-to-child transmission (PMTCT).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Pooled total plasma IgA, IgM and IgG. A Plasma IgA (mg/dL) level in the HIV infected HARRT treated and the control pregnant mothers showed non-significant (P > 0.05) difference. B Data indicated significantly lower (P < 0.0001) total plasma IgM level in the HIV infected HAART treated pregnant mothers compared to the control group. C Total plasma IgG level in the HIV infected HARRT treated pregnant mothers was significantly (P < 0.0001) higher compared to their control group.
Fig. 2
Fig. 2
Total plasma IgA, IgM and IgG at 1st, 2nd and 3rd Trimester. A There was non-significant—ns (P > 0.05) difference in plasma IgA through 1st, 2nd and 3rd trimesters in the HIV+ HAART treated and control subjects. B Plasma IgM in the HIV+ HAART treated pregnant women and control subjects showed non-significant (ns) difference (P > 0.05) throughout 1st, 2nd and 3rd trimester. C Plasma IgG levels at 1st and 3rd trimesters in the HIV infected HAART treated pregnant women were significantly higher (P = 0.0005; P < 0.0001) than that in the control group.
See this image and copyright information in PMC

References

    1. Borges-Almeida E, Milanez HM, Vilela MM, Cunha FG, Abramczuk BM, Reis-Alves SC, Metze K, Lorand-Metze I. The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC Infect Dis. 2011;11:38. doi: 10.1186/1471-2334-11-38. - DOI - PMC - PubMed
    1. Burns WR, Wang Y, Tang PC, Ranjbaran H, Iakimov A, Kim J, Cuffy M, Bai Y, Pober JS, Tellides G. Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma-inducible chemokines in rejecting human arteries. Am J Transpl. 2005;5:1226–1236. doi: 10.1111/j.1600-6143.2005.00892.x. - DOI - PubMed
    1. Clerici M, Seminari E, Suter F, Castelli F, Pan A, Biasin M, Colombo F, Trabattoni D, Maggiolo F, Carosi G, Maserati R. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive subjects with undetectable viremia. AIDS. 2000;14:109–116. doi: 10.1097/00002030-200001280-00005. - DOI - PubMed
    1. Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, Hoos D, Nakakeeto O, De Lay P. Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS ONE. 2013;8:e57778. doi: 10.1371/journal.pone.0057778. - DOI - PMC - PubMed
    1. Fiore S, Newell ML, Trabattoni D, Thorne C, Gray L, Savasi V, Tibaldi C, Ferrazzi E, Clerici M. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol. 2006;70:143–150. doi: 10.1016/j.jri.2005.12.001. - DOI - PubMed

MeSH terms